Two years in: revenue nearly doubled, 24/7 global support live, and SugarShot’s white-glove service model left intact

LOS ANGELES and SAN FRANCISCO, Aug. 11, 2026 — Treeline announced that SugarShot, the Los Angeles-based managed services provider, joined the company in August 2024 as its first design partner. In the two years since, SugarShot has nearly doubled its revenue while keeping the client teams that define its brand.

Treeline is challenging the decades-old acquisition playbook: that scale and efficiency come at the expense of the client experience. Treeline’s model inverts that assumption. SugarShot keeps its structure, leadership, and ways of working with clients. What it gains is engineering capabilities, institutional credibility, and ultimately, the ability to scale impact without sacrificing client experience.

That strategy has paid off; since August 2024, SugarShot has grown revenue nearly 100% by going deeper with existing clients and landing new, larger accounts. Headcount has grown 68%, all while service delivery quality continued to improve.

“By pairing the strongest companies and operators in this market with world-class engineering and go-to-market capabilities, Treeline can build and define the future of this industry,” said Peter Doyle, CEO of Treeline. “One that doesn’t depart from the value of people and high-touch service, but leverages software development, automation, and AI to provide a better experience to customers who are constantly growing and evolving.”

For clients, the SugarShot experience stayed consistent. “Clients are still able to work and interact with the same people who already know their environment and own the problem until it’s closed,” said Brandon Fox, Head of Technology at SugarShot. “What has changed is that I trust every ticket is triaged, worked, and escalated inside our service levels, which means I finally get to work on the business instead of in it.”

SugarShot has expanded the range of the work it can take on. Tina Grintjes, Director of Operations, said, “Historically, our conversations were primarily around managed IT, security, and technology operations. Today, through Treeline, we can have much broader conversations around AI, compliance, cloud infrastructure, and more. We can grow alongside our clients in ways we simply couldn’t before.”

Before joining Treeline, roughly 5% of SugarShot’s client base had significant overseas operations; today, about 50% of new clients do. SugarShot has also stood up a follow-the-sun support model, giving clients 24/7 coverage and eliminating the weekday on-call rotation for its technicians.

“We are now partnering with clients that we would never have partnered with if Treeline hadn’t pushed us to look at them differently, and there are also clients Treeline would never have won without SugarShot,” said Pam Boston, CEO of SugarShot. “It’s truly a two-way street. Treeline has given us not only the resources, but also the encouragement, to really run headfirst into opportunities that we might not have looked twice at in the past.”

SugarShot was Treeline’s first design partner. Treeline is excited to be applying learnings from the success with SugarShot as the business selectively brings additional partners into the model.

About SugarShot

SugarShot is a Los Angeles-based managed services provider, formed in 2018. The company delivers managed IT, cybersecurity, and technology solutions to mid-market companies, with a focus on healthcare and manufacturing. SugarShot is led by CEO Pam Boston and has been part of Treeline since August 2024.

About Treeline

Treeline is a modern IT and security partner for mid-market and scaling companies, delivering the ownership and accountability of an internal team without the cost of building one. Built on AI-native infrastructure and backed by Andreessen Horowitz, Treeline works with best-in-class service providers to bring that model to clients.

Media Contact: [email protected]

SOURCE Treeline, Inc.

After seven years of profitable growth, the bootstrapped company now operates at nine figures in annual recurring revenue.

MIAMI, Aug. 11, 2026 — Horatio, a global leader in AI-enabled business solutions and tech-powered talent, today marked seven years in business as a bootstrapped company operating at over nine figures in annual recurring revenue. Operating at this scale without outside capital places Horatio among less than 1% of companies that have achieved profitable recurring revenue through bootstrapped growth.

Founded in 2018 by Jose Herrera, Alex Ross, and Jared Karson, Horatio has grown from a startup focused on customer support into a global operation serving more than 125 clients across healthcare, fintech, ecommerce, and other high-growth industries. Today, the company operates at over nine figures in annual recurring revenue—all without raising outside capital.

“What started as a vision to build a better workplace and a better customer experience partner has grown beyond anything we could have imagined,” said Jose Herrera, CEO and Co-Founder of Horatio. “Reaching this milestone is a testament to our team, our clients, and our beliefs that customer experience can be a strategic driver of business growth when powered by exceptional people and the right technology.”

Over the past seven years, Horatio has expanded its footprint across the United States and Latin America, with operations in the Dominican Republic, Colombia, and Honduras. The company now employs more than 3,500 team members globally and continues to scale at 40% year-over-year, with 77% of customers expanding their team size and scope with the brand. 

Recent milestones include:

• Operating as a nine-figure annual recurring revenue business without outside capital
• Growing to more than 3,500 employees across the U.S. and Latin America
• Nearly doubling its workforce in 2024 to meet growing demand from ecommerce and technology companies
• Launching HoratioHX, the company’s healthcare-focused division, to support patient engagement, revenue cycle management, and healthcare operations
• Opening operations in Honduras, further strengthening Horatio’s nearshore delivery network and access to top bilingual talent across Latin America
• 3 out of 4 customers expand their team size and scope after partnering with Horatio

“What we’re most proud of isn’t just winning customers—it’s earning their trust over time. Today, 77% of our customers expand after their first engagement, which we believe is the strongest validation of our model,” said Herrera. “When we launched Horatio, we set out to challenge the perception of what outsourcing could be. The future of customer experience isn’t about replacing people with technology, it’s about combining exceptional talent with AI and operational excellence to deliver better outcomes at scale.”

As the company looks ahead, Horatio plans to continue its AI capabilities, consulting services, and regulated-industry expertise while deepening partnerships across healthcare, fintech, and ecommerce.  For more information, visit www.hirehoratio.com or follow @HireHoratio.

About Horatio
Horatio is a global leader in AI-enabled business solutions and tech-powered talent. The company combines AI-enabled business solutions with world-class global talent to help companies scale faster across customer experience, trust and safety, back-office operations, and other business-critical functions. Founded in 2018, Horatio partners with many of the world’s fastest-growing startups and enterprises, helping them build more efficient operations, deliver exceptional customer experiences, and unlock growth. With headquarters in New York City and Miami and operations across the Dominican Republic, Honduras, and Colombia, Horatio is committed to innovation, talent development, and creating economic opportunity throughout the Americas. Horatio is ISO/IEC 27001 certified, reinforcing its commitment to the highest standards of information security and data protection for clients operating in highly regulated industries, including healthcare and fintech.

Media contact: Mercedes Lovato at [email protected] 

SOURCE Horatio

ITHACA, N.Y., Aug. 11, 2026 — Soctera, Incorporated (Soctera) has closed $4 million in seed funding backed by Anorak Ventures and Multiball Capital, with additional participation from 9Yards Capital, Mana Ventures, and Red Bear Ventures. The company will use the funding to develop its power amplifiers: the electronic devices that dictate wireless signal range and fidelity for radar, electronic warfare, satellites, and telecommunications networks.

When a power amplifier overheats, the system it powers goes with it. Range collapses and signals distort. The increasing demands of modern systems have made heat the fundamental constraint on wireless performance. Soctera attacks that constraint at the semiconductor level, enabling longer-range detection and communication, clearer signals, and hardware that lasts.

“By co-optimizing the semiconductor stack electrically and thermally, we reduce the gallium nitride (GaN) content in each device by 20X and halve thermal resistance. We are now turning our materials-level advantage into qualified power amplifiers,” said Reet Chaudhuri, co-founder and CTO of Soctera.

“The people building next-generation radar and satellites are already asking for more than any amplifier can deliver,” said Austin Hickman, co-founder and CEO of Soctera. “This raise lets us answer them, scaling the team and the manufacturing to put that hardware in their hands.”

The company spun out of Cornell University’s Jena-Xing group, a top research lab in the field of wide bandgap electronics. Prior to the seed raise, Soctera won over $4.2 million in non-dilutive grant funding from the National Science Foundation, U.S. Army, U.S. Air Force, and the CHIPS Act to develop and demonstrate its core technology. As defense and space systems take on harder jobs at longer distances, the reach and reliability of every signal increasingly decides what those systems can do.

“The ability to immediately detect threats at greater range with improved fidelity is increasingly becoming a key advantage for the modern warfighter,” said Greg Castle, Managing Partner at Anorak Ventures. “The shift towards autonomous systems is accelerating the need for improved signal handling. Soctera’s technology will give the U.S. and our allies a key advantage for communication and detection both on and off the battlefield.”

About Soctera

Soctera builds power amplifiers that extend the range, fidelity, and reliability of modern systems that detect threats and carry critical communications. From defense radar and electronic warfare to satellite and commercial networks, Soctera is building the semiconductor foundation these next-generation systems will run on. Learn more at www.soctera.com or reach out at [email protected].

SOURCE Soctera, Inc.

SAN FRANCISCO, Aug. 11, 2026 — House of Student, a global student living technology company operating the world’s largest student housing marketplace with over 2.5 million verified student rooms across 25+ countries including the UK, US, Australia, Canada, New Zealand, UAE, Singapore, and 18 European nations, has raised $2 million in seed capital through a mix of equity and debt. The funding will accelerate product innovation, AI capabilities and global expansion.

The round is led by Saltwater Sutra, a New York-Mumbai based investment banking group, alongside Nirmitsu Inspirational Ventures. Other participants include Gautam Verlekar (co-founder, Saltwater Venture Sparks), Glen Fernandes (MD, Bank of New York Mellon), Richard McCallum (former MD & CEO, UK India Business Council), Ali Moosa (Exec-Vice Chairman, Singapore Gulf Bank), and other strategic investors. Existing investors from Unilodgers also continued their support.

The company was founded in 2025 by Vaibhav Verma, who earlier built Unilodgers, the world’s first student housing marketplace, bootstrapping it until the company reached $109 million in valuation. For Verma, House of Student isn’t a second venture but the continuation of a 15-year mission & responsibility towards students globally. Much of the original Unilodgers leadership, including leaders Ayushi Gupta and Deepak Bahuguna, has stayed on to build this next chapter.

Verma’s inspiration traces back to his own housing struggles as a student in London and Nottingham, UK, where he relied on classifieds and broken networks to find accommodation, a gap that led him to found Unilodgers on principles of trust and care.

“We never started with the ambition of building an accommodation company,” said Vaibhav Verma, Founder of House of Student. “Student housing was simply the first problem we wanted to solve. Today, our ambition is to become the world’s most trusted company around student life.”

The COVID-19 pandemic disrupted the sector significantly, including Unilodgers, prompting Verma and his team to ask a bigger question: what responsibility do they have to support students throughout their university journey? The answer was House of Student.

About House of Student 

Headquartered in San Francisco with teams across India, the UK, and the Middle East, House of Student operates the world’s largest student housing marketplace, with a broader mission to become the most trusted company around student life globally.

Learn more: https://houseofstudent.com/

SOURCE House of Student

Brown joins from Smartsheet with two decades of engineering leadership and a track record of
scaling AI-native development

SANTA BARBARA, Calif., Aug. 11, 2026 — Invoca, the AI-powered leader in revenue execution, today announced the appointment of JB Brown as Chief Technology Officer. Brown joins as the company expands its AI agents that run buyer journeys for consumer brands, following the June launch of Nico, its AI revenue conversion agent.

Brown comes to Invoca from Smartsheet, where he led the engineering organization through its transition to AI-native engineering and agentic development workflows.

At Invoca, he will own the engineering strategy and platform architecture as the company expands the Invoca Platform and the AI agents that run buyer journeys for marketing, engagement, and contact center teams, turning buyer interactions into revenue.

“JB has spent his career driving change by teaching and modeling the behaviors he wants to see, working alongside engineers to evolve how software gets built and shipped,” said Gregg Johnson, CEO, Invoca. “Teams that build with AI every day build better AI for customers. That is the connection JB makes, and it is why he will move our platform and our agents forward faster.”

Brown has spent the last several years working directly on agentic systems. At Smartsheet, he designed an agentic software development lifecycle, embedding specialized AI agents across architecture, implementation, testing, and operations. He is also a top 15 contributor to Roo Code, an open-source AI coding agent project, and most recently founded Prosponsive, where he has been building an agentic development framework and a personal autonomous agent platform.

“Invoca has built a rare combination of trusted first-party data and real AI expertise, and that foundation is what makes agentic technology genuinely useful for revenue teams,” said Brown. “The draw for me was an engineering culture where agentic development is already the way the work gets done rather than a pilot running on the side. That is how you attract the best engineers and turn raw velocity into a lasting competitive edge.”

Brown joins Invoca following the June 2026 launch of Nico and the release of the company’s 2026 Lead Conversion Benchmarks Report, an analysis of 70 million voice and SMS conversations that found leads referred from ChatGPT convert at the highest rate of any channel.

Explore open roles on the engineering team, along with several other opportunities across the business: https://www.invoca.com/company/careers. 

More Information

About Invoca

Invoca is an AI-powered revenue execution platform that connects marketing, commerce, and contact center teams to orchestrate seamless buyer journeys and turn every interaction into measurable, profitable growth. The Invoca platform features deep integrations with leading technology partners, enabling revenue teams to connect paid media investments to business outcomes, improve digital engagement, and convert more leads into sales.

Invoca’s AI vision centers on using trustworthy, first-party data to deliver AI that is intelligent, authentic, and empathetic – connecting digital and human experiences to build lasting customer relationships. Top consumer brands, including Mayo Clinic, Mutual of Omaha, and Verizon, rely on Invoca to power profitable growth. Invoca has raised $184M from leading investors, including Upfront Ventures, Accel, Silver Lake Waterman, H.I.G. Growth Partners, and Salesforce Ventures. For more information, visit www.invoca.com.

SOURCE Invoca

This Marks the Company’s Sixth Consecutive Year on the List, Earning Its Place Among the Nation’s Most Successful Independent Businesses

SAN JOSE, Calif., Aug. 11, 2026 — The Pipeline Group (TPG) today announced it has been named on the 2026 Inc. 5000 list, the annual list of the fastest-growing private companies in America. The list is the most prestigious ranking of the nation’s most successful independent and entrepreneurial businesses, recognizing companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Past honorees include companies such as Microsoft, Meta, Chobani, Oracle, and Patagonia.

This marks TPG’s sixth consecutive year on the Inc. 5000 list. The company has also been featured on Inc.’s Fastest Growing Companies in the Pacific list three years in a row (2024-2026) and named an Inc. 2025 Power Partner.

“No matter how many times we find ourselves on the Inc. 5000 List, we’re incredibly honored to be in conversation with such an elite group of organizations,” said Ken Jisser, Founder and CEO of TPG. “This is a reflection of our discipline, partnerships, and desire to build a superior level of performance for our clients. We’re looking forward to what the future holds.”

In 2026, TPG is focused on scalable growth, from expanding its leadership team to launching TPG Terminal, an enterprise platform created to provide revenue leaders a single source of truth for pipeline performance. The company is focused on pipeline predictability, operational discipline, and market leadership.  

This year’s Inc. 5000 recognizes a new class of companies redefining what growth looks like. From AI and advanced manufacturing to healthcare, consumer products, and professional services, these businesses are expanding their impact, creating jobs and proving that entrepreneurial ambition continues to fuel the U.S. economy. Among the 5,000 companies on the list, the median three-year revenue growth rate was 130%, and those companies have collectively added more than 627,208 jobs to the U.S. economy over the past three years.

For the full Inc. 5000 list, honoree company profiles, and a searchable database by industry and location, please visit: www.inc.com/inc5000.

“Every company on the Inc. 5000 has a story of perseverance, smart decision making, and a refusal to sit still,” says Mike Hofman, editor-in-chief of Inc. “Their growth reflects more than strong financial performance–it reflects creativity, resilience, and the customer focus required to build companies that make a lasting impact. We congratulate all honorees on this significant achievement.”

Inc. 5000 List Methodology
Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2022 to 2025. To qualify, companies must have been founded and generating revenue by March 31, 2022. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2025. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2022 is $100,000; the minimum for 2025 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons.

About The Pipeline Group
The Pipeline Group (TPG) is the premier business development and pipeline performance management partner for B2B technology companies. With more than 600 employees worldwide, TPG combines rigorously trained Sales Development Representatives (SDRs), proprietary technology, and data-driven execution to deliver a predictable, high-quality pipeline. Recognized on the Inc. 5000 list for six consecutive years and named an Inc. Power Partner in 2025 and 2026, TPG is trusted by enterprise and growth-stage companies to launch new products, enter new markets, and build durable, measurable revenue engines. For more information, visit https://www.thepipelinegroup.io/about.

About Inc.
Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com.

TPG Media Contact

Bob Spoerl
[email protected]
(773) 453-2444

SOURCE The Pipeline Group

After steadying the firm through transition and following one of its most impressive exits to date, the seven-year OurCrowd veteran will be stepping in as the company’s official CEO, appointed by OurCrowd’s board of directors    

TEL-AVIV, Israel, Aug. 11, 2026 — OurCrowd, the global platform that provides its community of investors with access to venture and private-market opportunities mostly reserved for venture funds and the world’s largest institutions, today announced that Cali Chill will transition from Acting CEO & COO to Chief Executive Officer. Cali stepped in as Acting CEO in mid-2025, when founder Jon Medved chose to step back from day-to-day management for medical reasons, and is now appointed by the Board to officially lead the firm into its next era.

The appointment caps a defining year. Since mid-2025, Cali and OurCrowd’s Executive Leadership Team have restored firm-wide stability, sharpened focus around fewer, higher-conviction deals, including known AI giants, launched a full assessment and monetization plan for the existing portfolio and rebuilt workflows to transition the investment and asset management platform into the age of AI-driven investing.    

Earlier this month, the company announced a mega exit of its portfolio company BioCatch, acquired by Visa in a reported $2.4 billion transaction, where OurCrowd invested early and followed on through growth. The transaction is subject to customary closing conditions, including receipt of applicable regulatory approvals; and expected to close by the end of Visa’s fiscal second quarter of 2027.

“OurCrowd was founded to bring institutional-grade access and rigor to individual accredited investors. We don’t assume access; we earn it through years of building our trusted network and disciplined diligence on every deal. Having spent seven years embedding this rigor across our firm, I am committed to scaling that discipline, delivering the responsibility and returns our investors expect. I am honoured to lead the firm forward,” said Chill in the editorial interview.

The Board has appointed Cali to continue leading the company with rigor and trust. “I am very pleased with the Company’s progress and accomplishments over the past several quarters,” said Ben Plotkin, Chairman of OurCrowd’s Board of Directors. “Since Cali took charge of the operation, the firm has been managed with increasing financial discipline and operational focus. Having worked closely with Cali since the leadership transition of 2025, I am excited about OurCrowd’s prospects, and the Board has full confidence in Cali’s ability to lead the firm through this next chapter.”

Cali Chill has spent seven years at OurCrowd, rising through senior leadership roles across legal, funds and investment strategy before being named Acting CEO and COO. He joined the firm as General Counsel, later elevated to Chief Legal Officer. He served as Head of Funds & CLO overseeing the firm’s in-house and third-party investment funds, and most recently served as Chief Investment Officer and Chair of OurCrowd’s Investment Committee, with direct oversight over the firm’s deal flow. Before OurCrowd, Cali was General Counsel of Nasdaq-listed Answers Corporation and of AFCV Holdings, a private-equity-backed technology investor. He holds a joint LLB/MBA from Bar Ilan University and is licensed to practice law in Israel and New York.

About OurCrowd

OurCrowd is a global venture investment platform built on a simple premise: the best private-market opportunities should not be reserved exclusively for the world’s largest institutions. Since 2013, OurCrowd has built one of the industry’s most extensive private investment networks – investing alongside sovereign wealth funds, leading institutions, corporations, family offices and angel investors. Access to the platform is by qualification, not by default: every investor is screened against strict accreditation and suitability criteria before joining a global club that today spans nearly 8,000 active members, globally.

Headquartered in Jerusalem, with offices in Tel Aviv and Toronto, OurCrowd raised more than $2.6 billion in commitments across 500+ portfolio companies and dozens of funds, generating 73 exits to date – including this month’s $2.4 billion reported acquisition of portfolio company BioCatch by Visa.

For more information, visit: www.ourcrowd.com

Contact: Cali Chill, [email protected]

Photo: https://mma.prnewswire.com/media/3008751/Cali_Chill_OurCrowd.jpg

SOURCE OurCrowd

STOCKHOLM, Aug. 11, 2026 —

• EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company’s USD 152 million Series B financing
• The financing will support the initiation of the global Phase 3 HEROIC study evaluating engasertib, a potential first treatment for hereditary hemorrhagic telangiectasia, a rare genetic vascular disease characterized by severe nosebleeds, chronic anemia, and life-threatening vascular abnormalities, with no approved therapies
• EQT Life Sciences will draw on its experience supporting biotechnology companies through last-stage clinical development to work alongside the management team in executing the company’s development strategy

EQT Life Sciences is pleased to announce its participation in Vaderis Therapeutics’ USD 152 million Series B financing through one of its managed funds, with a USD 17.5 million investment. The financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, Perceptive Advisors, Kalehua Capital and existing investors Medicxi and Droia. The proceeds will support Vaderis with capital needs through potential regulatory approval of engasertib, the company’s lead program for hereditary hemorrhagic telangiectasia (HHT).

Vaderis Therapeutics is a Swiss clinical-stage biotechnology company developing targeted therapies for rare vascular diseases. Its lead program, engasertib, is being developed as a potential first treatment specifically developed for HHT, a rare inherited blood vessel disorder affecting ~1 in 3,800. HHT causes recurrent and severe nosebleeds (epistaxis), chronic anemia and potentially life-threatening vascular abnormalities for which there are currently no approved therapies.

The financing and initiation of the company’s global Phase 3 trial, HEROIC, follows publication of positive proof-of-concept and long-term extension data for engasertib in The New England Journal of Medicine, which demonstrated clinically meaningful and sustained improvements across multiple measures of disease in patients with HHT. These data established the scientific foundation for advancing engasertib into pivotal development and its potential to address the significant unmet needs of patients living with HHT.

EQT Life Sciences will support Vaderis Therapeutics as it advances engasertib through its Phase 3 development and towards potential regulatory approval. Drawing on its experience supporting biotechnology companies through last-stage clinical development, EQT Life Sciences will work alongside the management team to help execute the company’s development strategy.

Christoph Broja, CFA, Partner at EQT Life Sciences, who will join the Vaderis board as an observer, said: “HHT remains a serious, lifelong disease with no approved treatment anywhere in the world, despite affecting tens of thousands of patients. Engasertib’s proof of concept data gave us real conviction in the science, and we’re pleased to support the Vaderis team as they advance engasertib into Phase 3 with the goal of potentially bringing these patients their first dedicated therapy.”

Azmi Nabulsi, MD, MPH, President and Chief Executive Officer of Vaderis Therapeutics, said: “Today represents a defining moment for HHT patients. Closing this financing and initiating HEROIC as the first Phase 3 study utilizing a molecule specifically developed for HHT marks an exciting new chapter. This milestone reflects the dedication of our patients, investigators, study teams, and advocacy organizations, to whom we extend our deepest gratitude. We are also thankful to our investors for their confidence and support, which have been essential in bringing us to this point.”

Contact
EQT Press Office,
[email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-life-sciences-participates-in-vaderis-therapeutics–usd-152-million-series-b-financing,c4381729

The following files are available for download:

• $152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia
• Provides the company with capital needs through potential U.S. regulatory approval of engasertib
• Marks the company’s transition into pivotal-stage development with initiation of the global Phase 3 HEROIC study evaluating engasertib, a once daily oral medication, in patients with moderate-to-severe hereditary hemorrhagic telangiectasia (HHT)

BASEL, Switzerland and LINCOLNSHIRE, Ill., Aug. 11, 2026 — Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, today announced the closing of a private $152 million Series B financing and initiation of HEROIC, the company’s global Phase 3 clinical study evaluating engasertib (VAD044) in patients with hereditary hemorrhagic telangiectasia (HHT).

Together, these milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically developed for people living with HHT, a rare genetic vascular disorder that currently has no approved treatment options worldwide.

The Series B financing, supported by both new and existing investors, reflects strong confidence in the potential of engasertib to address significant unmet needs in HHT.  The proceeds from the financing are expected to fund the company’s planned operations through regulatory submissions and potential U.S. regulatory approval.

Following the closing, Vaderis’ Board of Directors comprises Giovanni Mariggi of Medicxi, Colin Walsh of Goldman Sachs Alternatives, Giuliano Marostica of TCGX, Francesco Draetta of Omega Funds, Nick Williams of Medicxi, Azmi Nabulsi, President and Chief Executive Officer of Vaderis, and Rahul Ballal, who serves as an independent director.

The financing and initiation of HEROIC follows publication of positive proof-of-concept and long-term extension data for engasertib in The New England Journal of Medicine, which demonstrated clinically meaningful and sustained improvements across multiple measures of disease in patients with HHT. These data established the scientific foundation for advancing engasertib into pivotal development and its potential to address the significant unmet needs of patients living with HHT.

“Today represents a defining moment for HHT patients,” said Azmi Nabulsi, MD, MPH, President and Chief Executive Officer of Vaderis Therapeutics. “Closing this financing and initiating HEROIC as the first Phase 3 study utilizing a molecule specifically developed for HHT marks an exciting new chapter. This milestone reflects the dedication of our patients, investigators, study teams, and advocacy organizations, to whom we extend our deepest gratitude. We are also thankful to our investors for their confidence and support, which have been essential in bringing us to this point.”

“Having partnered with Vaderis since its inception, Medicxi has seen the company consistently translate cutting-edge science into meaningful clinical progress,” said Giovanni Mariggi, co-founder and Partner, Medicxi and Chairman of Vaderis Therapeutics. “The advancement of engasertib into Phase 3 represents the culmination of years of disciplined execution, scientific innovation and close collaboration with the HHT community. Building on the important contributions of clinicians and scientists that have advanced the field, we are proud to continue supporting Vaderis as it pioneers a regulatory pathway for therapies specifically developed for HHT, while working to bring the first such treatment to patients.

“Vaderis has generated compelling clinical evidence supporting targeted AKT inhibition as a novel treatment approach for HHT,” said Colin Walsh, PhD, Managing Director, Life Sciences at Goldman Sachs Alternatives. “The company’s strong scientific foundation, disciplined execution and clear focus on addressing a significant unmet medical need gave us conviction in both the financing and the Phase 3 program.”

“We are pleased to partner with Vaderis and a high-quality investor syndicate to advance engasertib through this important stage of development,” added Giuliano Marostica, Managing Partner, TCGX.

Phase 3 HEROIC Study Now Underway

HEROIC is a global, randomized, double-blind, placebo-controlled Phase 3 clinical study designed to evaluate the efficacy and safety of once-daily oral engasertib in patients with moderate-to-severe HHT. The study is expected to enroll patients across sites in North America, South America and Europe.

“HHT remains a serious, lifelong disease that places a substantial burden on patients, yet there are still no approved therapies,” said Hanny Al-Samkari, MD, Associate Professor of Medicine at Harvard Medical School, The Peggy S. Blitz Endowed Chair in Hematology/Oncology at Mass General Brigham Cancer Institute, and Principal Investigator of the HEROIC study. “As the Principal Investigator of HEROIC, I believe this study has been thoughtfully designed to rigorously evaluate engasertib in a larger patient population and confirm the encouraging findings from the earlier proof-of-concept study.”

About Engasertib (VAD044)
Engasertib is an investigational oral selective allosteric inhibitor of AKT1/2 being developed for the treatment of hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder characterized by recurrent bleeding and arteriovenous malformations. By targeting dysregulated signaling pathways implicated in vascular malformations, engasertib is designed to address the underlying pathophysiology of disease.

Engasertib has not been approved for use in any country for any indication.

About HHT
Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic vascular disorder (prevalence ~1 in 3,800) characterized by recurrent severe epistaxis, anemia, and visceral arteriovenous malformations (AVMs). Despite the significant disease burden, there are currently no approved therapies for HHT globally.

About Vaderis Therapeutics
Vaderis Therapeutics is a science-driven biopharmaceutical company focused on discovering and advancing transformative treatments for rare vascular diseases. By targeting the underlying pathophysiology, the company aims to bring first-in-class targeted therapies to patients in need. Vaderis is headquartered in Basel, Switzerland with a U.S. subsidiary in Lincolnshire, Illinois. For more information, visit www.vaderis.com.

Forward-Looking Statement

This press release contains forward-looking statements regarding the development, regulatory review, and potential approval of engasertib and related programs, the anticipated initiation, timing, and execution of clinical trials, the expected use of proceeds from the financing, and the company’s anticipated operational runway. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements, including due to risks, uncertainties, and the inherent complexities of clinical development, regulatory review, financing activities, manufacturing, and other factors.

This press release does not constitute an offer or solicitation for the purchase or disposal of, trading or any transaction in any securities of Vaderis Therapeutics in any jurisdiction.

Medical Information

Engasertib has not been approved for use in any country for any indication. Information in this press release is for medical and scientific reference only and is not intended to promote, recommend, or suggest use of this product. The safety and efficacy of engasertib have not been established by any regulatory authority.

SOURCE Vaderis Therapeutics AG